MOONLAKE IMMUNO (MLTX)
(Real Time Quote from BATS)
$44.79 USD
+1.73 (4.02%)
Updated Aug 8, 2024 12:01 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
MLTX 44.79 +1.73(4.02%)
Will MLTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MLTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MLTX
Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade
Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
MLTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54%
Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates
MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for MLTX
Barclays Keeps Their Hold Rating on MoonLake Immunotherapeutics (MLTX)
Buy Rating for MoonLake Immunotherapeutics Backed by Strong Prospects for Lead Candidate and Financial Stability
MoonLake Immunotherapeutics: A Strong Buy on Solid Financials and Promising Clinical Trials
MoonLake Immunotherapeutics (MLTX) Receives a Buy from TD Cowen
MoonLake Immunotherapeutics GAAP EPS of -$0.39